Savara Inc SVRA
Institutional shares held
158 Million
55.6K
calls
600
puts
Total value of holdings
$450M
$157K
calls
$1K
puts
Market Cap
$324M
114,043,000
Shares Out.
Institutional ownership
138.79%
# of Institutions
141
We take great care to ensure that the data presented and summarized in this overview for Savara Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SVRA
View all-
Nea Management Company, LLC Timonium, MD24.5MShares$69.5 Million5.37% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$41.4 Million12.07% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$35.1 Million6.2% of portfolio
-
Vestal Point Capital, LP New York, NY10.8MShares$30.6 Million1.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.66MShares$24.6 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.31MShares$23.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.03MShares$22.8 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY7.96MShares$22.6 Million0.61% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.53MShares$21.4 Million1.16% of portfolio
-
Farallon Capital Management LLC San Francisco, CA6.84MShares$19.4 Million0.11% of portfolio
Latest Institutional Activity in SVRA
Top Purchases
Top Sells
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Transactions at SVRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2025
|
Robert Matthew Lutz Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38,263
-9.57%
|
$76,526
$2.83 P/Share
|
|
Dec 16
2024
|
David L Lowrance Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-6.16%
|
$75,000
$3.33 P/Share
|
|
Dec 16
2024
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
54,702
-3.44%
|
$164,106
$3.31 P/Share
|
|
Dec 16
2024
|
Richard J Hawkins |
SELL
Open market or private sale
|
Direct |
8,000
-10.63%
|
$24,000
$3.32 P/Share
|
|
Dec 13
2024
|
Anne Erickson Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,263
-4.03%
|
$54,789
$3.21 P/Share
|
|
Dec 13
2024
|
David L Lowrance Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,350
-5.66%
|
$73,050
$3.21 P/Share
|
|
Dec 13
2024
|
David L Lowrance Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
12,000
-2.71%
|
-
|
|
Dec 13
2024
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
92,593
-5.5%
|
$277,779
$3.21 P/Share
|
|
Dec 12
2024
|
Anne Erickson Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+18.09%
|
-
|
|
Dec 12
2024
|
Robert Matthew Lutz Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+20.0%
|
-
|
|
Dec 12
2024
|
Braden C. Parker Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+16.0%
|
-
|
|
Dec 12
2024
|
David L Lowrance Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+18.44%
|
-
|
|
Dec 12
2024
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+19.2%
|
-
|
|
Dec 12
2024
|
Raymond Dennis Pratt Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.05%
|
-
|
|
Dec 12
2024
|
Nevan C Elam |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+39.02%
|
-
|
|
Dec 12
2024
|
Richard J Hawkins |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+34.71%
|
-
|
|
Dec 12
2024
|
An Van Es Johansson |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+39.02%
|
-
|
|
Dec 12
2024
|
David A Ramsay |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+1.66%
|
-
|
|
Dec 12
2024
|
Joseph S Mc Cracken |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+13.75%
|
-
|
|
Nov 19
2024
|
Joseph S Mc Cracken |
BUY
Open market or private purchase
|
Direct |
20,000
+8.66%
|
$40,000
$2.95 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.21M
Shares
From
13
Insiders
| Grant, award, or other acquisition | 1.09M shares |
|---|---|
| Open market or private purchase | 120K shares |
Sell / Disposition
324K
Shares
From
9
Insiders
| Payment of exercise price or tax liability | 225K shares |
|---|---|
| Open market or private sale | 87.7K shares |
| Bona fide gift | 12K shares |